Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4′-hydroxymethyl-α-pyrrolidinobutyrophenone

Biochemical Pharmacology

Volumn 74, Issue 3, 2007, Pages 511-520

  Peters, Frank T ^a   Dragan, Calin A ^b   Wilde, Désirée R ^a   Meyer, Markus R ^a   Zapp, Josef ^c   Bureik, Matthias ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b PomBioTech GmbH   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

4 methyl pyrrolidinobutyrophenone; Cytochrome P450; Drug; MPBP; Schizosaccharomyces pombe; Synthesis

Indexed keywords

4' HYDROXMETHYL ALPHA PYRROLIDINOBUTYROPHENONE; 4' METHYL ALPHA PYRROLIDINOBUTYROPHENONE; CHLORIDE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DRUG METABOLITE; HYDROGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BIOTECHNOLOGICAL PRODUCTION; CELL DENSITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG PURITY; DRUG SYNTHESIS; FUNGAL STRAIN; FUNGUS CULTURE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; LINEAR SYSTEM; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PH MEASUREMENT; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DETECTION; SCHIZOSACCHAROMYCES POMBE; ULTRAVIOLET RADIATION; YEAST;

BIOTECHNOLOGY; BUTYROPHENONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PYRROLIDINES; RECOMBINANT PROTEINS; SCHIZOSACCHAROMYCES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 34250716024     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.05.010     Document Type: Article

References (41)

1. Maurer H.H., Sauer C., and Theobald D.S. Toxicokinetics of drugs of abuse: Current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine [review]. Ther Drug Monit 28 (2006) 447-453
2. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34 (2002) 83-448
3. Guengerich F.P. Human Cytochrome P450 Enzymes. In: Ortiz-de-Montellano P.R. (Ed). Cytochrome P450 - Structure, Mechanism, and Biochemistry (2005), Kluwer Academic/Plenum Publishers, New York 377-530
4. Lindner P. Schizosaccharomyces pombe n. sp., ein neuer Gährungserreger. Wochenschr Brauerei 1893; 10:1298-300.
5. Kaufer N.F., Simanis V., and Nurse P. Fission yeast Schizosaccharomyces pombe correctly excises a mammalian RNA transcript intervening sequence. Nature 318 (1985) 78-80
6. Russell P., and Nurse P. Schizosaccharomyces pombe and Saccharomyces cerevisiae: a look at yeasts divided. Cell 45 (1986) 781-782
7. Jones R.H., Moreno S., Nurse P., and Jones N.C. Expression of the SV40 promoter in fission yeast: identification and characterization of an AP-1-like factor. Cell 53 (1988) 659-667
8. Brys R., Nelles L., van der S.E., Silvestre N., Huylebroeck D., and Remacle J.E. Identical cis-acting elements and related trans-acting factors control activity of nonviral promoter in Schizosaccharomyces pombe and mammalian cells. DNA Cell Biol 17 (1998) 349-358
9. Giga-Hama Y., and Kumagai H. Expression system for foreign genes using the fission yeast Schizosaccharomyces pombe. Biotechnol Appl Biochem 30 Pt 3 (1999) 235-244
10. Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A., et al. The genome sequence of Schizosaccharomyces pombe. Nature 415 (2002) 871-880
11. Alfa C., Fantes P., Hyams J., McLeod M., and Warbrick E. Experiments with Fission Yeast. A Laboratory Course Manual (1993), Cold Spring Harbor Press, Cold Spring Harbor, NY
12. Dragan C.A., Zearo S., Hannemann F., Bernhardt R., and Bureik M. Efficient conversion of 11-deoxycortisol to cortisol (hydrocortisone) by recombinant fission yeast Schizosaccharomyces pombe. FEMS Yeast Res 5 (2005) 621-625
13. Dragan C.A., Hartmann R.W., and Bureik M. A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem 21 (2006) 547-556
14. Dragan C.A., Blank L.M., and Bureik M. Increased TCA cycle activity and reduced oxygen consumption during cytochrome P450-dependent biotransformation in fission yeast. Yeast 23 (2006) 779-794
15. Bureik M., Schiffler B., Hiraoka Y., Vogel F., and Bernhardt R. Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochemistry 41 (2002) 2311-2321
16. Yasumori T., Chen L.S., Li Q.H., Ueda M., Tsuzuki T., Goldstein J.A., et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem Pharmacol 57 (1999) 1297-1303
17. Roesner P., Junge T., Fritschi G., Klein B., Thielert K., and Kozlowski M. Neue synthetische Drogen: Piperazin-, Procyclidin- und alpha-Aminopropiophenonderivate. Toxichem Krimtech 66 (1999) 81-90
18. Springer D., Fritschi G., and Maurer H.H. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 796 (2003) 253-266
19. Springer D., Peters F.T., Fritschi G., and Maurer H.H. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 773 (2002) 25-33
20. Springer D., Peters F.T., Fritschi G., and Maurer H.H. New designer drug 4′-methyl-alpha-pyrrolidinohexanophenone: Studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 789 (2003) 79-91
21. Springer D., Fritschi G., and Maurer H.H. Metabolism and toxicological detection of the new designer drug 4′-methoxy-α-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793 (2003) 331-342
22. Springer D., Fritschi G., and Maurer H.H. Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793 (2003) 377-388
23. Peters F.T., Meyer M.R., Fritschi G., and Maurer H.H. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 824 (2005) 81-91
24. Fauquet J.P., Morel E., Demarty C., and Rapin J.R. Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch Int Pharmacodyn Ther 224 (1976) 325-337
25. Servin A., Fauquet J.P., Jacquot C., and Rapin J.R. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem Pharmacol 27 (1978) 1693-1694
26. Meltzer P.C., Butler D., Deschamps J.R., and Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J Med Chem 49 (2006) 1420-1432
27. Stille G., Ackermann H., Eichenberger E., and Lauener H. Comparative pharmacological study of a new central stimulant, 1-p-tolyl-1-oxo-2-pyrrolidino-n-pentane HCl. Arzneim -Forsch 13 (1963) 871-877
28. Holliday A.R., Morris R.B., and Sharpley R.P. Compound 84/F 1983 compared with D-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 6 (1964) 192-200
29. Heimann H., and Lukacs G. Experimental psychological differentiation of the effect of 2 psychostimulants (F-1983 and amphetamine) in humans. Psychopharmacologia 8 (1965) 79-90
30. Soderholm S., Viukari N.M., and Rimon R. The psychotropic effect of the Pyrovalerone (F-1983), placebo, the milieu therapy and mental condition of the patients in forensic psychiatry. Nervenarzt 47 (1976) 88-93
31. Goldberg J., Gardos G., and Cole J.O. A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int Pharmacopsychiatry 8 (1973) 60-69
32. Heinmann H., and Vetter K. Clinical studies of a new psychostimulant (F-1983). Schweiz Med Wochenschr 95 (1965) 306-309
33. Deniker P., Loo H., Cuche H., and Roux J.M. Abuse of pyrovalerone by drug addicts. Ann Med Psychol (Paris) 2 (1975) 745-748
34. Michaelis W., Russel J.H., and Schindler O. The metabolism of pyrovalerone hydrochloride. J Med Chem 13 (1970) 497-503
35. Lho D.S., Lee J., Kim S., Park J., and Shin H.S. Identification of a pyrovalerone metabolite in the rat by gas chromatography-mass spectrometry and determination of pyrovalerone by gas chromatography-nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 687 (1996) 253-259
36. Shin H.S., Shin Y.S., Lee S., and Park B.B. Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J Anal Toxicol 20 (1996) 568-572
37. Shin H., and Park J. Identification of the new metabolites of pyrovalerone by various derivatization methods in the rat urine. Korean Biochem J 27 (1994) 357-361
38. Westphal F, Junge T, Rosner P, Fritschi G, Klein B, Girreser U. Mass spectral and NMR spectral data of two new designer drugs with an alpha-aminophenone structure: 4′-Methyl-alpha-pyrrolidinohexanophenone and 4′-methyl-alpha-pyrrolidinobutyrophenone. Forensic Sci Int 2007 [Epub ahead of print].
39. Suga M., and Hatakeyama T. A rapid and simple procedure for high-efficiency lithium acetate transformation of cryopreserved Schizosaccharomyces pombe cells. Yeast 22 (2005) 799-804
40. Maurer H.H., Pfleger K., and Weber A.A. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and their Metabolites (2007), Wiley-VCH, Weinheim
41. Blanpain J.P., Ronjat M., Supply P., Dufour J.P., Goffeau A., and Dupont Y. The yeast plasma membrane H(+)-ATPase. An essential change of conformation triggered by H+. J Biol Chem 267 (1992) 3735-3740